Challenges in atrial fibrillation.

Hugo Ten Cate, Harry J Crijns, Ron Pisters

Journal: Advances in cardiology 2012;47():155-64

PMID: 22906910

Full Text on S. Karger AG, Basel, Switzerland View on PubMed

Abstract

Atrial fibrillation (AF) is an extremely prevalent dynamic chronic disease often associated with underlying heart disease, making the management of AF challenging. The antithrombotic management - and in particular the use of antiplatelet agents herein - is challenging as it depends on the (adequate) assessment of the risk of stroke and major bleeding. We therefore focus on the current (recommended) use of antiplatelet agents, address the caveats, and provide clinical tools to assess risk of stroke and major bleeding. Furthermore, we discuss novel antithrombotic agents to provide a future perspective of the role of antiplatelet agents in the antithrombotic management of AF patients.

Address: Department of Cardiolog, Maastricht University Medical Centre, Maastricht, The Netherlands. [email protected]

DOI: 10.1159/000338058

Link outs

Free resources

Medical:

https://medlineplus.gov/bloodthinners.html

Subscription / membership required

Full Text Sources:

https://doi.org/10.1159/000338058

MeSH Terms: Aspirin, Atrial Fibrillation, Benzimidazoles, Clopidogrel, Dabigatran, Drug Therapy, Combination, Humans, International Normalized Ratio, Platelet Aggregation Inhibitors, Stroke, Ticlopidine, beta-Alanine